Olibolla (Guangzhou)Cosmetics Co., Ltd.

Olibolla (Guangzhou) Cosmetics Co., Ltd., as a highly recognized gold medal cosmetics supplier in China, has been deeply engaged in the private label cosmetics field for many years. With its outstanding quality and comprehensive services, it has established a solid reputation in the global market. The company's product matrix not only covers individual makeup items such as lipsticks, lip glosses, and eyeliner pens, but also provides a full range of solutions from basic base makeup to delicate eye makeup based on customer needs, meeting diverse demands such as the European market's preference for natural ingredients, the American market's pursuit of innovative formulas, and the Asian market's requirement for a fine skin feel.

Relying on a research and development technical team with over 10 years of experience, the company has continuously made breakthroughs in formula innovation. The team is composed of senior cosmetic chemists, dermatologists and color consultants. It closely follows global beauty trends and invests a large amount of resources every year in developing new formulas that meet international standards, such as gentle makeup series for sensitive skin, long-lasting formulas that last for 12 hours, and skin-nourishing products infused with plant extracts. Meanwhile, the R&D team has established strategic partnerships with multiple international raw material suppliers to ensure the safety and advancement of raw materials. All components have passed strict certifications such as the EU REACH and the US FDA, laying a solid foundation for product quality.

In the one-stop service of OEM and ODM, the company has demonstrated an efficient full-process control capability. From the product planning stage, professional consultants will provide customized solutions based on the client's brand positioning, target market and budget. The formula development stage adopts a modular system, which enables rapid adjustment of texture, color number and efficacy, meeting the flexible demands from small-scale trial produc